Low Endotoxin Recovery (LER): Causes, Risk and Investigation
Low Endotoxin Recovery (LER) is an important consideration in bacterial endotoxin testing when a product formulation reduces the measurable recovery of endotoxin added to a sample. This phenomenon is also called endotoxin masking, because endotoxin may become less available for detection by the analytical system, even though it hasn’t actually been destroyed.
LER is particularly relevant to certain complex pharmaceutical formulations. Current EMA guidance identifies formulations containing a combination of a surfactant (such as polysorbate) and a chelator (such as EDTA, citrate, phosphate, or histidine) as formulations where LER studies should be considered when the risk is identified.
Understanding Low Endotoxin Recovery matters because a result showing low recovery doesn’t necessarily mean the product contains little or no endotoxin the observed recovery can be affected by interaction between the formulation and the endotoxin itself, which complicates interpretation of the test.
What Is Low Endotoxin Recovery (LER)?
Low Endotoxin Recovery refers to reduced recovery of endotoxin that has been intentionally added, or spiked, into a pharmaceutical product sample during a bacterial endotoxin test. In a suitable recovery study, a known amount of endotoxin is added to the product and the amount recovered is measured. When recovered endotoxin decreases substantially over relevant conditions or time, this may indicate endotoxin masking. EMA describes LER as a reduced ability to detect spiked endotoxin in products tested using a compendial LAL assay or recombinant Factor C-based assay.
Simple example
Suppose a product sample is spiked with a known amount of endotoxin. If the expected spike is 1.0 EU/mL and only 0.3 EU/mL is recovered:
Recovery (%) = Recovered endotoxin / Added endotoxin × 100 Recovery = 0.3 / 1.0 × 100 = 30%
A low recovery result requires evaluation according to the applicable method, product-specific procedure, and regulatory expectations.
Why Is Low Endotoxin Recovery Important?
The purpose of bacterial endotoxin testing is to obtain a reliable measurement of endotoxin in the sample. If endotoxin becomes masked or otherwise unavailable to the detection system, the measured result may not accurately represent the amount actually present in the product an important quality concern, since a low analytical result could give a false sense of assurance.
LER should be evaluated using scientifically appropriate studies rather than assuming that a low recovery automatically represents a compliant product. FDA emphasizes the importance of demonstrating the reliability and accuracy of endotoxin testing for each product, including evaluation of recovery of low levels of added endotoxin.
https://pharmavk.com/method-suitability-test-microbiology/
What Causes Low Endotoxin Recovery?
The exact mechanisms behind LER aren’t completely understood. EMA notes that current knowledge suggests LER can be inherent to certain product formulations, with potential contributing factors involving interactions between endotoxin and formulation components.
1. Surfactants
Surfactants can interact with endotoxin aggregates and may alter how endotoxin is presented to the detection system. Examples include certain polysorbates used in pharmaceutical formulations.
2. Chelating Agents
Chelating agents can bind metal ions and may influence endotoxin structure or its interaction with the assay system. Examples mentioned in EMA guidance include EDTA, citrate, phosphate, and histidine.
3. Combination of Surfactants and Chelators
A combination of a surfactant and a chelator is particularly important when evaluating LER risk. The presence of both components doesn’t by itself prove LER will occur a product-specific assessment is still required.
4. Product Formulation
Other formulation characteristics can influence endotoxin recovery and assay performance, which is why bacterial endotoxin testing should be demonstrated suitable for the particular product rather than assumed to work identically across different formulations.
LER and Endotoxin Masking
LER and endotoxin masking are often used together the basic concept being that endotoxin may become less detectable by the analytical method because of interactions with the product formulation. This doesn’t necessarily mean the endotoxin has been destroyed, which is an important distinction: a low analytical recovery shouldn’t automatically be interpreted as evidence that endotoxin is absent from the product.
How Is an LER Study Performed?
The exact study design should be scientifically justified and appropriate for the product and analytical method, but a general approach follows five steps.
Step 1: Identify the LER Risk
Review the formulation and determine whether components associated with potential endotoxin masking are present, paying particular attention to combinations of surfactants and chelators.
Step 2: Prepare the Product Sample
The product is tested under conditions representative of the intended manufacturing and testing process. EMA recommends that LER studies use undiluted samples spiked with known amounts of endotoxin when evaluating identified LER risk.
Step 3: Spike with Known Endotoxin
A known quantity of endotoxin is added to the sample to determine whether the analytical method can recover it from the product matrix.
Step 4: Evaluate Recovery Over Time
Recovery is evaluated at predefined time points. EMA recommends the study reflect relevant manufacturing conditions, including applicable temperatures and potential manufacturing hold times.
Step 5: Compare Recovery With Acceptance Criteria
Observed recovery is evaluated against predefined criteria applicable to the study and method. EMA’s current Q&A recommends evaluating a minimum of four time points, considering two consecutive data points below 50% recovery as indicative of LER.
Example of LER Study Evaluation
| Time Point | Endotoxin Recovery |
|---|---|
| Initial | 85% |
| 24 hours | 68% |
| 48 hours | 48% |
| 72 hours | 35% |
This decreasing pattern would require investigation under the EMA approach described above, two consecutive results below 50% (48% and 35%, here) would be considered indicative of LER. This example is illustrative only; actual study design, time points, acceptance criteria, and interpretation should follow applicable regulatory and product-specific requirements.
What Is the Risk of LER?
The main concern with LER is the potential for underestimation of endotoxin during testing. If endotoxin becomes less detectable over time, a test performed after sufficient masking has occurred may produce a lower measured result than the product’s true endotoxin state which is why LER evaluation should consider realistic manufacturing conditions and potential product hold times. EMA specifically recommends that LER studies reflect relevant manufacturing temperatures and potential hold times.
LER Investigation: What Should Be Evaluated?
When LER is suspected or identified, the investigation should be scientifically structured, potentially evaluating: product formulation, surfactant concentration, chelator concentration, product pH, endotoxin concentration used for spiking, sample preparation, sample storage conditions, temperature, hold time, test method, reagent suitability, dilution conditions, recovery results, historical endotoxin data, and manufacturing process conditions. The investigation should determine whether the observed low recovery relates to the product formulation, analytical procedure, sample handling, or another factor.
https://pharmavk.com/oos-investigation-in-pharmaceutical-microbiology/
LER vs. Analytical Interference
LER shouldn’t automatically be treated as identical to every form of endotoxin-test interference. Analytical interference can include factors that cause inhibition (reducing assay response) or enhancement (increasing assay response), where formulation components interfere with detection more generally. Compendial bacterial endotoxin testing includes procedures for demonstrating a product doesn’t interfere with the test, and ICH Q4B Annex 14 recognizes harmonized pharmacopoeial bacterial endotoxin testing approaches, though the applicable pharmacopoeia should be followed for the specific method.
LER is more specifically associated with a time-dependent or formulation-related reduction in endotoxin recovery, and should be investigated accordingly.
What Can Be Done If LER Is Identified?
The mitigation strategy should be based on scientific evaluation and applicable regulatory requirements possible approaches include optimizing the compendial test method, evaluating an alternative endotoxin-testing approach, developing an appropriate sample-treatment or demasking strategy, reassessing sample preparation, establishing product-specific controls, reducing relevant product hold times where scientifically justified, strengthening manufacturing controls, or establishing appropriate endotoxin specifications.
EMA states that when LER is detected, an adequate mitigation strategy should be proposed, which may include optimization of the compendial method or development of an alternative method. Any treatment or method modification must itself be demonstrated suitable it shouldn’t simply be introduced because it increases recovery.
Can Dilution Solve LER?
Dilution can help with some forms of product interference, but it shouldn’t automatically be assumed to solve LER. The appropriate approach depends on the product, the mechanism of interference, the validated test method, and applicable acceptance criteria. For bacterial endotoxin testing, the selected dilution must stay within the applicable Maximum Valid Dilution (MVD) and should be demonstrated to provide reliable recovery an important distinction between routine assay interference and formulation-related endotoxin masking.
LER and Recombinant Endotoxin Tests
Bacterial endotoxin testing can use different analytical technologies. Traditional LAL methods include gel-clot, turbidimetric, and chromogenic approaches; recombinant approaches such as recombinant Factor C (rFC) are also available. USP General Chapter <85> describes bacterial endotoxin testing, while USP <86> covers testing using recombinant reagents, and USP’s current <1085> content discusses modern approaches and recombinant reagents in more depth.
Importantly, switching from one analytical platform to another shouldn’t be assumed to eliminate a product-related LER issue method suitability and product-specific evaluation remain essential regardless of platform.
LER and Regulatory Expectations
LER is specifically addressed by regulatory authorities because of its potential impact on the reliability of bacterial endotoxin testing. EMA’s current biological-medicinal-products Q&A recommends LER studies when the risk is identified, with specific expectations around undiluted samples, endotoxin spiking, relevant time points, manufacturing temperatures and hold times, interpretation of recovery, and mitigation strategies. For new marketing-authorisation applications, EMA states relevant LER study data should be included in the appropriate quality documentation.
FDA’s current March 2026 guidance on pyrogen and endotoxin testing provides recommendations concerning USP <85>, USP <161>, and related bacterial endotoxin testing approaches.
LER Investigation: Practical Flow
Identify LER Risk → Review Product Formulation → Perform Product-Specific Recovery Study → Evaluate Recovery Over Relevant Time Points → Assess Manufacturing Temperature and Hold Time → Determine Whether LER Is Present → Investigate Possible Causes → Define Scientifically Justified Mitigation → Verify Method Suitability → Document the Conclusion and Controls
Best Practices for Managing LER
- Understand the product formulation and identify potential LER risk factors
- Use a scientifically justified study design
- Evaluate undiluted samples where required, with appropriate endotoxin spike levels
- Include relevant manufacturing temperatures and consider actual manufacturing hold times
- Evaluate multiple time points against predefined acceptance criteria
- Investigate unexpected recovery trends
- Evaluate the suitability of the endotoxin test method
- Establish an appropriate mitigation strategy when LER is identified
- Document the scientific rationale and conclusions
- Maintain appropriate regulatory documentation
Frequently Asked Questions
What does LER stand for?
LER stands for Low Endotoxin Recovery.
What is endotoxin masking?
A situation in which endotoxin becomes less available for detection by the analytical system, resulting in reduced measured recovery without the endotoxin actually being destroyed.
What causes Low Endotoxin Recovery?
LER is associated with certain product formulations. EMA particularly highlights formulations containing combinations of surfactants and chelators as requiring attention when LER risk is identified.
How is LER investigated?
By spiking the product with a known amount of endotoxin and monitoring recovery at predefined time points under conditions relevant to manufacturing, including temperature and hold time where applicable.
What recovery level indicates LER?
Under current EMA guidance, two consecutive data points below 50% recovery are considered indicative of LER, with the study including at least four time points.
Can dilution eliminate LER?
Dilution may address some forms of analytical interference, but it shouldn’t automatically be considered a solution for LER the appropriate approach must be demonstrated suitable for the specific product and test method.
Is LER the same as endotoxin interference?
Not exactly. LER is a specific phenomenon involving reduced recovery of endotoxin, often tied to product formulation and time-dependent masking. Endotoxin interference is a broader concept that can include both inhibition and enhancement of the analytical response.
Conclusion
Low Endotoxin Recovery (LER) is an important consideration when evaluating bacterial endotoxin testing for certain pharmaceutical formulations. The key concern is that formulation-related endotoxin masking may reduce the measurable recovery of endotoxin and affect how the analytical result should be interpreted. A scientifically designed LER study should consider the product formulation, endotoxin spike, relevant manufacturing conditions, temperature, hold time, and recovery over appropriate time points.
When LER is identified, the appropriate response isn’t simply to repeat the test the product and analytical method should be investigated, and a scientifically justified mitigation strategy established. Understanding LER matters for pharmaceutical microbiologists, QC analysts, QA professionals, analytical scientists, and anyone involved in bacterial endotoxin testing and product quality.
References
